MX2008011074A - Metodo anticonceptivo oral multifasico de ciclo prolongado. - Google Patents

Metodo anticonceptivo oral multifasico de ciclo prolongado.

Info

Publication number
MX2008011074A
MX2008011074A MX2008011074A MX2008011074A MX2008011074A MX 2008011074 A MX2008011074 A MX 2008011074A MX 2008011074 A MX2008011074 A MX 2008011074A MX 2008011074 A MX2008011074 A MX 2008011074A MX 2008011074 A MX2008011074 A MX 2008011074A
Authority
MX
Mexico
Prior art keywords
estrogen
ethinyl estradiol
amount equivalent
phase
equivalent
Prior art date
Application number
MX2008011074A
Other languages
English (en)
Inventor
Herman Ellman
Original Assignee
Warner Chilcott Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Chilcott Co Inc filed Critical Warner Chilcott Co Inc
Publication of MX2008011074A publication Critical patent/MX2008011074A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Abstract

La invención proporciona un método multifásico de anticoncepción que comprende las etapas de: administrar consecutivamente a una mujer en edad fértil una composición de la fase 1 que contiene un progestógeno en una cantidad equivalente a aproximadamente 0.3 hasta aproximadamente 1.5 mcg de acetato de noretindrona y un estrógeno en una cantidad equivalente a aproximadamente 5 hasta aproximadamente 15 mcg de etnil estradiol durante aproximadamente 7 hasta aproximadamente 14 días; una composición de la fase III que contiene un progestógeno en una cantidad equivalente a aproximadamente 0.3 hasta aproximadamente 1.5 mcg del acetato de noretindrona un estrógeno en una cantidad equivalente a aproximadamente 10 hasta aproximadamente 25 mcg de etinil estradiol durante aproximadamente 14 hasta aproximadamente 22 días; una composición de la fase III que contiene un progestógeno en una cantidad equivalente a aproximadamente 0.3 hasta aproximadamente 1.5 mcg de acetato de noretindrona y un estrógeno en una cantidad equivalente a aproximadamente 15 hasta aproximadamente 35 mcg de etinil estradiol durante aproximadamente 20 hasta aproximadamente 31 días; y una composición de la fase IV opcional que contiene (i) un estrógeno en una cantidad equivalente a aproximadamente 5 hasta aproximadamente 20 mcg del etinil estradiol, o (ii) un placebo o un componente no esteroidal, o (iii) una combinación de (i) y (ii), durante aproximadamente 2 hasta aproximadamente 8 días. La cantidad equivalente de etinil estradiol del estrógeno en cada una de las fases II y III sucesivas es de al menos 5 mcg mayor que la cantidad equivalente del etinil estradiol del estrógeno en la fase inmediatamente precedente.
MX2008011074A 2006-03-02 2007-02-09 Metodo anticonceptivo oral multifasico de ciclo prolongado. MX2008011074A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77806706P 2006-03-02 2006-03-02
US79265306P 2006-04-18 2006-04-18
PCT/US2007/003508 WO2007106264A2 (en) 2006-03-02 2007-02-09 Extended cycle multiphasic oral contraceptive method

Publications (1)

Publication Number Publication Date
MX2008011074A true MX2008011074A (es) 2008-09-10

Family

ID=38229300

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008011074A MX2008011074A (es) 2006-03-02 2007-02-09 Metodo anticonceptivo oral multifasico de ciclo prolongado.

Country Status (8)

Country Link
US (1) US8063030B2 (es)
EP (1) EP1993531B1 (es)
CA (1) CA2640520C (es)
ES (1) ES2558030T3 (es)
IL (1) IL193013A (es)
MX (1) MX2008011074A (es)
SG (1) SG172654A1 (es)
WO (1) WO2007106264A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049142A2 (en) * 2003-11-14 2005-06-02 Warner Chilcott Company, Inc. Graduated estrogen contraceptive
US20070111975A1 (en) * 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
WO2013090117A1 (en) 2011-12-13 2013-06-20 Arstat, Inc. A multiphasic contraceptive regimen for oral combination drug formulation of progestin and estrogen
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP3145489A1 (en) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
ES2877186T3 (es) 2015-06-18 2021-11-16 Estetra Sprl Comprimido orodispersable que contiene estetrol
US11147771B2 (en) 2015-06-18 2021-10-19 Estetra Sprl Orodispersible dosage unit containing an estetrol component
PL3310346T3 (pl) 2015-06-18 2021-10-25 Estetra Sprl Dyspergowalna w ustach tabletka zawierająca estetrol
TN2017000499A1 (en) 2015-06-18 2019-04-12 Mithra Pharmaceuticals S A Orodispersible dosage unit containing an estetrol component
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE35724E (en) * 1982-04-28 1998-02-03 Bio-Technology General Corp. Contraception system and method
US4962098A (en) * 1987-06-15 1990-10-09 Warner-Lambert Company Graduated estrogen contraceptive
US5010070A (en) * 1987-06-15 1991-04-23 Warner-Lambert Company Graduated estrogen contraceptive
DE4313926A1 (de) * 1993-04-28 1994-11-03 Jenapharm Gmbh Pharmazeutisches Mehrphasenpräparat zur hormonalen Kontrazeption
DE4411585A1 (de) * 1994-03-30 1995-10-05 Schering Ag Pharmazeutisches Kombinationspräparat zur hormonalen Kontrazeption
DE19525017A1 (de) 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
DE19531936A1 (de) 1995-08-17 1997-02-20 Schering Ag Kombinationspräparat zur Kontrazeption, Kits diese enthaltend und eine Methode diese verwendend
DE19540253C2 (de) * 1995-10-28 1998-06-04 Jenapharm Gmbh Mehrphasenpräparat zur Kontrazeption auf der Basis natürlicher Estrogene
CN1119999C (zh) * 1996-07-26 2003-09-03 惠氏公司 口服避孕药
US5898032A (en) 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US6251956B1 (en) 1998-08-20 2001-06-26 Ortho Pharmaceutical Corporation Combination progestin oral contraceptive regimen
DE19739916C2 (de) 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
CA2448271A1 (en) 2001-05-23 2002-11-28 Panterhei Bioscience B.V. Means and method for hormonal contraception
WO2003049744A1 (en) 2001-12-05 2003-06-19 Barr Laboratories, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US20030219471A1 (en) 2002-03-11 2003-11-27 Caubel Patrick Michel Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens
US20040142914A1 (en) 2002-03-11 2004-07-22 Friedman Andrew Joseph Extended transdermal contraceptive regimens
CA2478206A1 (en) 2002-03-11 2003-09-25 Patrick Michel Caubel Sulfatase inhibiting continuous progestogen contraceptive regimens
US7772219B2 (en) 2003-05-02 2010-08-10 Teva Women's Health, Inc. Methods of hormonal treatment utilizing extended cycle contraceptive regimens
CN101001631B (zh) 2003-07-16 2014-08-06 特卫华妇女健康有限公司 利用连续给予雌激素的避孕方案的激素治疗方法
BRPI0414945A (pt) 2003-10-01 2006-11-07 Janssen Pharmaceutica Nv regimes contraceptivos trifásicos estendidos
WO2005049142A2 (en) * 2003-11-14 2005-06-02 Warner Chilcott Company, Inc. Graduated estrogen contraceptive
US20050113350A1 (en) 2003-11-26 2005-05-26 Bernd Duesterberg Extended use combination comprising estrogens and progestins
ES2397983T3 (es) * 2004-03-19 2013-03-12 Warner Chilcott Company, Llc Procedimiento anticonceptivo oral multifásico de ciclo prolongado
DE102004019743B4 (de) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
WO2005113506A1 (en) * 2004-05-14 2005-12-01 Irm Llc Compounds and compositions as ppar modulators
EP1898953B1 (en) * 2005-06-29 2012-12-05 Warner Chilcott Company, LLC Quadraphasic continuous graduated estrogen contraceptive

Also Published As

Publication number Publication date
ES2558030T3 (es) 2016-02-01
WO2007106264A3 (en) 2008-05-02
IL193013A0 (en) 2009-08-03
US20070207945A1 (en) 2007-09-06
CA2640520C (en) 2014-04-22
SG172654A1 (en) 2011-07-28
US8063030B2 (en) 2011-11-22
IL193013A (en) 2011-11-30
EP1993531B1 (en) 2015-10-14
EP1993531A2 (en) 2008-11-26
WO2007106264A2 (en) 2007-09-20
CA2640520A1 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
MX2008011074A (es) Metodo anticonceptivo oral multifasico de ciclo prolongado.
MX2007013137A (es) Regimen anticonceptivo con dosificacion de estrogeno ampliada.
CA2609336C (en) Quadraphasic continuous graduated estrogen contraceptive
CA2542854A1 (en) Graduated estrogen contraceptive
WO2005092441A3 (en) Extended cycle multiphasic oral contraceptive method
JP2007535519A5 (es)
JP2009512658A5 (es)
JP2008540482A5 (es)
RU2009120528A (ru) Способы гормональной терапии возрастающими дозами в режиме пролонгированного цикла
TR200101826T2 (tr) Üç-fazlı ağızdan alınan gebelik önleyici ilaç
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
WO2006042021B1 (en) Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
RS50972B (sr) Farmaceutski sastav koji sadrži gestagene i/ili estrogene i 5-metil-(6s)-tetrahidrofolate
HRP20100513T1 (en) Multi-phase contraceptive preparation based on a natural estrogen
AR065816A1 (es) Regimen anticonceptivo oral
DE69731092D1 (de) Orales contrazeptivum
EA200701389A1 (ru) Твёрдая пероральная лекарственная форма для контрацепции
HRP20090256T1 (en) Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method
NO20072687L (no) Farmasoytisk prevensjonspreparat
PL1937274T3 (pl) Zastosowanie walerianianu estradiolu w połączeniu z dienogestem do doustnej terapii dysfunkcyjnego krwawienia macicznego wraz z doustną antykoncepcją
MXPA06004547A (es) Anticonceptivo estrogenico graduado

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FG Grant or registration